LILRB4 and acute myeloid leukemia: FTO overexpression induced by the hypomethylating agent decitabine in AML cells markedly increased the expression of the critical immune checkpoint protein LILRB4, which is 40-50 times more abundant than endogenous PD-L1 and PD-L2 in AML cell lines.